Nautilus Biotechnology (NAUT) Total Liabilities (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Total Liabilities of $32.5 million for Q2 2026, down 2.7% sequentially from $33.4 million in Q1 2026, and up 1.15% YoY from $32.1 million in Q2 2025.
Nautilus Biotechnology (NAUT) Total Liabilities (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Total Liabilities for 7 years, with the latest figure at $32.5 million in Q2 2026.
- Quarterly Total Liabilities rose 1.15% year-over-year to $32.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $32.5 million (up 1.15% YoY) and the FY2025 annual result came in at $34.1 million, changed 0.37% from the prior year.
- Total Liabilities fell to $32.5 million in Q2 2026 per NAUT's latest filing, from $33.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $42.2 million in Q1 2023 and troughed at $31.8 million in Q3 2025.
- A 5-year average of $35.9 million and a median of $34.6 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 956.92% in 2022, then retreated 15.42% in 2024.
- Over 5 years, Total Liabilities stood at $35.1 million in 2022, then grew by 14.47% to $40.2 million in 2023, then declined by 15.42% to $34.0 million in 2024, then grew by 0.37% to $34.1 million in 2025, then fell by 4.91% to $32.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $32.5 million, $33.4 million, and $34.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | 32.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.46 Mn |
| Mar 31, 2026 | 33.36 Mn |
| Dec 31, 2025 | 34.14 Mn |
| Sep 30, 2025 | 31.78 Mn |
| Jun 30, 2025 | 32.10 Mn |
| Mar 31, 2025 | 33.26 Mn |
| Dec 31, 2024 | 34.01 Mn |
| Sep 30, 2024 | 36.27 Mn |
| Jun 30, 2024 | 37.47 Mn |
| Mar 31, 2024 | 39.16 Mn |
| Dec 31, 2023 | 40.21 Mn |
| Sep 30, 2023 | 41.06 Mn |
| Jun 30, 2023 | 41.09 Mn |
| Mar 31, 2023 | 42.17 Mn |
| Dec 31, 2022 | 35.13 Mn |
| Sep 30, 2022 | 33.97 Mn |
| Jun 30, 2022 | 34.15 Mn |
| Mar 31, 2022 | 34.96 Mn |
| Dec 31, 2021 | 34.87 Mn |
| Sep 30, 2021 | 7.50 Mn |